PLK2
MOLECULAR TARGETpolo like kinase 2
PLK2 (polo like kinase 2) is targeted by 13 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting PLK2
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | ruxolitinib | 4.23 | 68 |
| 2 | bosutinib | 4.08 | 58 |
| 3 | bi 2536 | 4.01 | 54 |
| 4 | tae 684 | 3.43 | 30 |
| 5 | fedratinib | 3.40 | 29 |
| 6 | dovitinib | 3.09 | 21 |
| 7 | lestaurtinib | 3.04 | 20 |
| 8 | volasertib | 2.94 | 18 |
| 9 | thymoquinone | 2.89 | 17 |
| 10 | r 406 | 2.83 | 16 |
| 11 | pha 665752 | 2.71 | 14 |
| 12 | gsk 461364 | 2.40 | 10 |
| 13 | Wortmannin | 1.10 | 2 |
About PLK2 as a Drug Target
PLK2 (polo like kinase 2) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 13 compounds with documented PLK2 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
PLK2 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.